| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(05)64525-4 |
| P698 | PubMed publication ID | 8709723 |
| P2093 | author name string | G Gahrton | |
| O Ringdén | |||
| J Aschan | |||
| B Lönnqvist | |||
| G Kumlien | |||
| P2860 | cites work | Graft-versus-myeloma effect in two cases | Q71060552 |
| P433 | issue | 9023 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 346 | |
| P577 | publication date | 1996-08-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Graft-versus-myeloma effect | |
| P478 | volume | 348 |
| Q37088191 | A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97 |
| Q39112978 | A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma? |
| Q62588671 | A graft-versus-colonic cancer effect of allogeneic stem cell transplantation |
| Q34135678 | Allogeneic bone marrow transplantation with reduced conditioning (RC-BMT). |
| Q34326524 | Allogeneic hematopoietic cell transplantation for multiple myeloma |
| Q74234624 | Allogeneic hematopoietic cell transplantation for multiple myeloma |
| Q73177265 | Allogeneic stem cell transplantation for multiple myeloma |
| Q73311840 | Bone marrow and peripheral blood stem cell transplantation in multiple myeloma |
| Q40901324 | Bone marrow transplantation using unrelated donors for haematological malignancies |
| Q73375198 | Donor leukocyte infusions for multiple myeloma |
| Q36013444 | Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma |
| Q26771331 | Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity |
| Q41031177 | Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation |
| Q90156172 | Immunotherapy of multiple myeloma |
| Q41525599 | Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. |
| Q34473121 | Is there still a role for allogeneic stem-cell transplantation in multiple myeloma? |
| Q35651684 | Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma |
| Q30486842 | Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting |
| Q91893611 | Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation |
| Q37151207 | Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo |
| Q35121623 | Recent Developments in Hematopoietic Stem Cell Transplantation for Multiple Myeloma |
| Q80764931 | Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma |
| Q35060002 | Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation |
| Q42588915 | Role of allogeneic transplantation in multiple myeloma in the era of new drugs |
| Q37391117 | Role of autologous and allogeneic stem cell transplantation in myeloma |
| Q89777563 | Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma |
| Q36902825 | The allogeneic dilemma |
| Q36556492 | The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma |
| Q44104454 | The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants |
| Q82374037 | Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de |
Search more.